Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Education Library
  3. ESMO Books
  4. ESMO Handbooks
  5. Clinical Pharmacology of Anti-Cancer Agents
  6. Factsheets on Anti-Cancer Agents

Neratinib

Growth Factor Receptor Targeting – Irreversible Pan-HER Tyrosine Kinase Inhibitor (EGFR, HER2, HER4)

Description of the anti-cancer agent neratinib; an irreversible pan-HER tyrosine kinase inhibitor.

ESMO members: your membership includes full access to ESMO's Anti-Cancer Agents Factsheets. Sign in now to gain access to this page.

Not yet an ESMO member? Find out more about the benefits of becoming an ESMO member.

Useful links

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.